Hong Kong Biotech Stock News

SEHK:1530
SEHK:1530Biotechs

Why 3SBio (SEHK:1530) Is Down 10.1% After HK$3.12 Billion Follow-on Equity Offering And Portfolio Shift

3SBio Inc. recently completed a follow-on equity offering of HK$3.12 billion via a subsequent direct listing, issuing 105,169,500 ordinary shares at HK$29.62 each. The fundraise, paired with the planned divestment of its cash-generating hair-loss unit, underlines 3SBio’s push to become a focused innovator in late-stage biopharmaceuticals. With the shares posting a 10.14% seven-day decline, we’ll explore how this capital raise and portfolio refocus reshape 3SBio’s investment narrative. Find...
SEHK:3328
SEHK:3328Banks

How Investors Are Reacting To Bank of Communications (SEHK:3328) Capital Raise and Interim Dividend Decision

Bank of Communications Co., Ltd. recently approved a 2025 interim cash dividend of RMB1.563 per 10 shares and updated its interim dividend distribution arrangements, while also clarifying withholding tax rules for different categories of shareholders. In parallel, the bank completed a very large capital increase to RMB88.36 billion through the issuance of over 14 billion new A Shares, which can reinforce its regulatory capital base and support future business growth. We’ll examine how the...
SEHK:3
SEHK:3Gas Utilities

Hong Kong and China Gas (SEHK:3) Valuation After Major AWS Cloud and AI Modernization Drive

Hong Kong and China Gas (SEHK:3) just pushed a big chunk of its core infrastructure onto Amazon Web Services with partner eCloudvalley, aiming for up to 40% lower IT costs and 99.99% uptime on mission critical systems. See our latest analysis for Hong Kong and China Gas. The HK$7.18 share price has held up reasonably well this year, with a 17.5% year to date share price return and a 24.8% one year total shareholder return suggesting improving sentiment as investors warm to its gradual...
SEHK:291
SEHK:291Beverage

How ESG-Linked Incentives and Awards Could Reshape China Resources Beer (SEHK:291)'s Long-Term Investment Story

China Resources Beer (Holdings) Company Limited was recently named a winner for both Corporate Governance and ESG Excellence Awards at the 2025 Hong Kong Corporate Governance and ESG Excellence Awards, reflecting independent recognition of its governance structures and sustainability focus. The awards highlight how China Resources Beer is tying ESG performance to management incentives and actively addressing climate change, underlining an emphasis on long-term value creation and risk...
SEHK:1099
SEHK:1099Healthcare

Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership

Sinopharm Group (SEHK:1099) is back in focus after Shanghai Henlius Biotech moved to renew their long running distribution framework, extending Sinopharm’s role in distributing Henlius products from 2026 through 2028. See our latest analysis for Sinopharm Group. The renewed Henlius deal lands while Sinopharm’s HK$20.36 share price has seen a modest 1 day share price return of 1.09% but a softer 30 day share price return of 4.77%, with a more reassuring 5 year total shareholder return of...